Zacks: Brokerages Expect Galectin Therapeutics Inc. (NASDAQ:GALT) Will Post Earnings of -$0.10 Per Share

Equities analysts expect that Galectin Therapeutics Inc. (NASDAQ:GALTGet Rating) will report earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics reported earnings per share of ($0.11) during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.1%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Galectin Therapeutics will report full year earnings of ($0.42) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.42) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALTGet Rating) last issued its earnings results on Thursday, March 31st. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.07.

GALT has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Galectin Therapeutics in a research note on Friday, April 1st. Zacks Investment Research upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 19th. Finally, StockNews.com initiated coverage on Galectin Therapeutics in a research note on Sunday. They set a “sell” rating for the company.

Galectin Therapeutics stock opened at $1.58 on Wednesday. The business has a 50-day simple moving average of $1.71 and a two-hundred day simple moving average of $2.18. The company has a market cap of $93.76 million, a P/E ratio of -3.04 and a beta of 1.64. Galectin Therapeutics has a 52-week low of $1.46 and a 52-week high of $4.57. The company has a quick ratio of 4.63, a current ratio of 4.63 and a debt-to-equity ratio of 79.37.

Several large investors have recently made changes to their positions in GALT. Virtu Financial LLC bought a new position in shares of Galectin Therapeutics during the 4th quarter valued at approximately $37,000. Buckingham Strategic Wealth LLC bought a new position in shares of Galectin Therapeutics during the 3rd quarter valued at approximately $42,000. Commonwealth Equity Services LLC bought a new position in shares of Galectin Therapeutics during the 3rd quarter valued at approximately $46,000. Raymond James & Associates bought a new position in shares of Galectin Therapeutics during the 3rd quarter valued at approximately $51,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in shares of Galectin Therapeutics by 25.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock valued at $61,000 after acquiring an additional 6,015 shares during the period. Institutional investors own 12.35% of the company’s stock.

Galectin Therapeutics Company Profile (Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Recommended Stories

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.